Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Poland transposes EU Braille format requirements for drug packaging

This article was originally published in SRA

Executive Summary

As of 1 November 2008, marketing authorisation holders in Poland will be required to use the Braille format on human drugs packaging. The Polish ministry of health has already started a consultation process on the draft decree introducing the change, which is a result of amendments made in the EU pharmaceutical legislation in 2004. Recently, the ministry also issued a separate decree concerning the labeling of veterinary medicines. To date, packaging requirements for human and veterinary drugs have been regulated in one decree, which was adopted in 2002.

You may also be interested in...



MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins

In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.

EMA Acts To Freeze GVK Drugs, Guard Against Shortages

The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.

EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages

EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel